PLoS ONE (Jan 2012)

Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development.

  • Ariane Desselle,
  • Tanguy Chaumette,
  • Marie-Hélène Gaugler,
  • Denis Cochonneau,
  • Julien Fleurence,
  • Nolwenn Dubois,
  • Philippe Hulin,
  • Jacques Aubry,
  • Stéphane Birklé,
  • François Paris

DOI
https://doi.org/10.1371/journal.pone.0045423
Journal volume & issue
Vol. 7, no. 11
p. e45423

Abstract

Read online

Inhibiting the growth of tumor vasculature represents one of the relevant strategies against tumor progression. Between all the different pro-angiogenic molecular targets, plasma membrane glycosphingolipids have been under-investigated. In this present study, we explore the anti-angiogenic therapeutic advantage of a tumor immunotherapy targeting the globotriaosylceramide Gb3. In this purpose, a monoclonal antibody against Gb3, named 3E2 was developed and characterized. We first demonstrate that Gb3 is over-expressed in proliferative endothelial cells relative to quiescent cells. Then, we demonstrate that 3E2 inhibits endothelial cell proliferation in vitro by slowing endothelial cell proliferation and by increasing mitosis duration. Antibody 3E2 is further effective in inhibiting ex vivo angiogenesis in aorta ring assays. Moreover, 3E2 treatment inhibits NXS2 neuroblastoma development and liver metastases spreading in A/J mice. Immunohistology examination of the NXS2 metastases shows that only endothelial cells, but not cancer cells express Gb3. Finally, 3E2 treatment diminishes tumor vessels density, proving a specific therapeutic action of our monoclonal antibody to tumor vasculature. Our study demonstrates that Gb3 is a viable alternative target for immunotherapy and angiogenesis inhibition.